Clinical Genitourinary Cancer 2009-08-01

Reversal of docetaxel resistance with bevacizumab and thalidomide.

Yang-Min Ning, William D Figg, William L Dahut

Index: Clin. Genitourin. Cancer 7(2) , E37-8, (2009)

Full Text: HTML

Abstract

Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

Related Compounds

  • docetaxel trihydra...
  • Docetaxel

Related Articles:

Losartan competitively inhibits CYP2C8-dependent paclitaxel metabolism in vitro.

2014-01-01

[Biol. Pharm. Bull. 37(9) , 1550-4, (2014)]

The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.

2008-05-01

[Eur. J. Cancer 44(7) , 912-20, (2008)]

Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.

2009-01-01

[Clin. Cancer Res. 15(1) , 238-46, (2009)]

Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment

2010-01-01

[Eur. J. Cancer 46 , 3022-36, (2010)]

Novel therapeutic strategies in development for prostate cancer.

2008-01-01

[Expert Opin. Investig. Drugs 17(1) , 13-22, (2008)]

More Articles...